Rhythm Pharmaceuticals Inc.
RYTM
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
120.9% downsideOvervalued by 120.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.83 Billion |
|---|---|
| Enterprise Value | $8.00 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.11 |
| Beta | 1.88 |
| Outstanding Shares | 67,974,193 |
Return
| Return on Equity | -169.28% |
|---|---|
| Return on Assets | -47.04% |
| Return on Invested Capital | -54.28% |
Valuation & Multiples
| P/E Ratio | -36.48 |
|---|---|
| PEG | -294.01 |
| Price to Sales | 38.06 |
| Price to Book Ratio | 114.17 |
| Enterprise Value to Revenue | 36.82 |
| Enterprise Value to EBIT | -43.44 |
| Enterprise Value to Net Income | -39 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 1.85 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1332▼ 59.72% |
|---|---|
| Total Calls | 159,900▼ 58.83% |
| Total Puts | 21,300▼ 92.49% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.01%▼ 3.27% |
|---|---|
| Total Invested | $6.42B▼ 17.70% |
| Investors Holding | 291▲ 7.00% |
ESG Score
No data
About Rhythm Pharmaceuticals Inc.
90 employees
CEO: Hunter Smith Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the mel...
Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policy, which is critical for the commercial success of high-cost orphan drugs like setmelanotide.
This committee directly oversees the FDA and the drug approval process, which is the primary driver of Rhythm's stock value and operational viability.